PD-1抗动脉粥样硬化的作用机制及研究进展
The Mechanism and Research Progress of PD-1 in Anti Atherosclerosis
DOI: 10.12677/ACM.2023.131123, PDF,   
作者: 秦 涛：济宁医学院，山东 济宁；杨 彬*：济宁市第一人民医院，山东 济宁
关键词: 动脉粥样硬化；程序性细胞死亡-1；炎症；氧化应激；Atherosclerosis (AS)； Programmed Cell Death 1 (PD-1)； Inflammation； Oxidative Stress
摘要: 程序性细胞死亡-1 (PD-1)是一种跨膜蛋白，被认为是免疫应答的共同抑制因子。动脉粥样硬化会引起冠心病、脑卒中和其他器官发生继发性病变，严重威胁人们的身体健康。研究发现PD-1抗体可以通过抑制炎症反应、减少氧化应激、抗凝、调脂、降血压、促进糖代谢、调控平滑肌细胞增殖和迁移、减少病理性新生血管数量、保护血管内皮细胞等途径影响动脉粥样硬化进程。查阅近些年相关文献对PD-1抗动脉粥样硬化的作用机制及研究进展作一综述。
Abstract: Programmed cell death 1 (PD-1) is a transmembrane protein, which is considered to be a co-inhibitor of immune response. Atherosclerosis can cause secondary lesions in coronary heart disease, stroke and other organs, which seriously threaten people’s health. The study found that PD-1 antibody can affect the hardening process of arterial atherosclerosis by inhibiting inflamma-tory reaction, reducing oxidative stress, anticoagulation, regulating lipid, lowering blood pressure, promoting glucose metabolism, regulating the proliferation and migration of smooth muscle cells, reducing the number of pathological new blood vessels, and protecting vascular endothelial cells. The mechanism and research progress of PD-1 in anti atherosclerosis were reviewed by reviewing the relevant literature in recent years.
文章引用：秦涛, 杨彬. PD-1抗动脉粥样硬化的作用机制及研究进展[J]. 临床医学进展, 2023, 13(1): 847-853. https://doi.org/10.12677/ACM.2023.131123

参考文献

[1] Libby, P. (2021) The Changing Landscape of Atherosclerosis. Nature, 592, 524-533. [Google Scholar] [CrossRef] [PubMed]
[2] Sharpe, A.H. and Pauken, K.E. (2018) The Diverse Functions of the PD1 Inhibitory Pathway. Nature Reviews Immunology, 18, 153-167. [Google Scholar] [CrossRef] [PubMed]
[3] Han, Y., et al. (2018) Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Frontiers in Immunology, 9, 1774. [Google Scholar] [CrossRef] [PubMed]
[4] Wolf, D. and Ley, K. (2019) Immunity and Inflammation in Ath-erosclerosis. Circulation Research, 124, 315-327. [Google Scholar] [CrossRef] 
[5] Wiktorin, G., et al. (2019) Histamine Targets Mye-loid-Derived Suppressor Cells and Improves the Anti-Tumor Efficacy of PD-1/PD-L1 Checkpoint Blockade. Cancer Immunology, Immunotherapy: CII, 68, 163-174. [Google Scholar] [CrossRef] [PubMed]
[6] Van Damme, H., Dombrecht, B., Kiss, M., et al. (2021) Thera-peutic Depletion of CCR8+ Tumor-Infiltrating Regulatory T Cells Elicits Antitumor Immunity and Synergizes with An-ti-PD-1 Therapy. Journal for Immunotherapy of Cancer, 9, e001749. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, Y., Liu, S., Yang, Z., et al. (2021) Anti-PD-1/L1 Lead-In be-fore MAPK Inhibitor Combination Maximizes Antitumor Immunity and Efficacy. Cancer Cell, 39, 1375-1387.e6. [Google Scholar] [CrossRef] [PubMed]
[8] Kiyokawa, J., Kawamura, Y., Ghouse, S.M., et al. (2021) Modifi-cation of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clinical Cancer Research, 27, 889-902. [Google Scholar] [CrossRef] 
[9] Marchio, P., Guerra-Ojeda, S., Vila, J.M., et al. (2019) Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxidative Medicine and Cellular Lon-gevity, 2019, Article ID: 8563845. [Google Scholar] [CrossRef] [PubMed]
[10] Khatana, C., Saini, N.K., Chakrabarti, S., et al. (2020) Mechanistic In-sights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 5245308. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, Y., Gao, D., Jin, L., et al. (2022) NADPH Selective Depletion Nanomedicine-Mediated Radio-Immunometabolism Regulation for Strengthening Anti-PDL1 Therapy against TNBC. Advanced Science (Weinh). e2203788. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, W., Chapman, N.M., Zhang, B., et al. (2019) Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation-Induced Immune Suppression. Cancer Research, 79, 2909-2922. [Google Scholar] [CrossRef] 
[13] Yu, Y.R., Imrichova, H., Wang, H., et al. (2020) Disturbed Mitochondrial Dynamics in CD8+ TILs Reinforce T Cell Exhaustion. Nature Immunology, 21, 1540-1551. [Google Scholar] [CrossRef] [PubMed]
[14] Jiménez-Fernández, M., Rodríguez-Sinovas, C., Cañes, L., et al. (2022) CD69-oxLDL Ligand Engagement Induces Programmed Cell Death 1 (PD-1) Expression in Human CD4 + T Lymphocytes. Cellular and Molecular Life Sciences, 79, 468. [Google Scholar] [CrossRef] [PubMed]
[15] Park, J.H., Kang, Y.J., et al. (2016) Microfluidics for Simulta-neous Quantification of Platelet Adhesion and Blood Viscosity. Scientific Reports, 6, Article No. 24994. [Google Scholar] [CrossRef] [PubMed]
[16] Ramasamy, I. (2004) Inherited Bleeding Disorders: Disorders of Platelet Adhesion and Aggregation. Critical Reviews in Oncology/Hematology, 49, 1-35. [Google Scholar] [CrossRef] 
[17] Dharmapuri, S., Özbek, U., Lin, J.Y., et al. (2020) Predictive Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Advanced Hepatocellular Carcinoma Pa-tients Treated with Anti-PD-1 Therapy. Cancer Medicine, 9, 4962-4970. [Google Scholar] [CrossRef] [PubMed]
[18] Miyata, J., Fukunaga, K., Iwamoto, R., et al. (2013) Dysregulated Synthe-sis of Protectin D1 in Eosinophils from Patients with Severe Asthma. Journal of Allergy and Clinical Immunology, 131, 353-360.e602. [Google Scholar] [CrossRef] [PubMed]
[19] Vibhakar, R., Juan, G., Traganos, F., Darzynkiewicz, Z. and Finger, L.R. (1997) Activation-Induced Expression of Human Programmed Death-1 Gene in T-Lymphocytes. Experimental Cell Research, 232, 25-28. [Google Scholar] [CrossRef] [PubMed]
[20] Poznyak, A., Grechko, A.V., Poggio, P., et al. (2020) The Diabetes Mellitus—Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Interna-tional Journal of Molecular Sciences, 21, 1835. [Google Scholar] [CrossRef] [PubMed]
[21] Patsoukis, N. (2015) PD-1 Alters T-Cell Metabolic Reprogramming by Inhibiting Glycolysis and Promoting Lipolysis and Fatty Acid Oxidation. Nature Communications, 6, 6692. [Google Scholar] [CrossRef] [PubMed]
[22] He, F., et al. (2021) Mitophagy-Mediated Adipose Inflammation Con-tributes to Type 2 Diabetes with Hepatic Insulin Resistance. The Journal of Experimental Medicine, 218, e20201416. [Google Scholar] [CrossRef] [PubMed]
[23] Marette, A., Liu, Y. and Sweeney, G. (2014) Skeletal Muscle Glucose Metabolism and Inflammation in the Development of the Metabolic Syndrome. Reviews in Endocrine and Metabolic Disorders, 15, 299-305. [Google Scholar] [CrossRef] [PubMed]
[24] Thomas-Wohlever, J. and Lee, I. (2002) Kinetic Characterization of the Peptidase Activity of Escherichia coli Lon Reveals the Mechanistic Similarities in ATP-Dependent Hydrolysis of Peptide and Protein Substrates. Biochemistry, 41, 9418-9425. [Google Scholar] [CrossRef] [PubMed]
[25] Dent, P., Booth, L., Roberts, J.L., Poklepovic, A. and Hancock, J.F. (2020) (Curcumin+Sildenafil) Enhances the Efficacy of 5FU and Anti-PD1 Therapies in Vivo. Journal of Cellular Physiology, 235, 6862-6874. [Google Scholar] [CrossRef] [PubMed]
[26] Shayan, G., Srivastava, R., Li, J., Schmitt, N., Kane, L.P. Ferris, R.L. (2016) Adaptive Resistance to Anti-PD1 Therapy by Tim-3 Upregulation Is Mediated by the PI3K-Akt Pathway in Head and Neck Cancer. Oncoimmunology, 6, e1261779. [Google Scholar] [CrossRef] 
[27] Sundarraj, K., Raghunath, A., Panneerselvam, L. and Pe-rumal, E. (2021) Fisetin Inhibits Autophagy in HepG2 Cells via PI3K/Akt/mTOR and AMPK Pathway. Nutrition and Cancer, 73, 2502-2514. [Google Scholar] [CrossRef] [PubMed]
[28] Zou, Y., Gan, C.L., Xin, Z., et al. (2021) Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3β Activity and Tau Hyperphosphorylation in Alzheimer’s Disease Mouse Models. Frontiers in Cell and Developmental Biology, 9, Article ID: 769229. [Google Scholar] [CrossRef] [PubMed]
[29] 杨思琪, 王健, 童兰, 齐灵垚, 陈旭, 蔡琳. 血管平滑肌细胞凋亡对动脉粥样硬化作用的研究进展[J]. 中南大学学报(医学版), 2021, 46(8): 872-876.
[30] 王梦楠, 秦合伟, 郭宁, 宋雪梅, 牛雨晴, 孙孟艳. 姜黄素抗动脉粥样硬化的作用机制及研究进展[J]. 中医药学报, 2022, 50(7): 116-120. [Google Scholar] [CrossRef] 
[31] Theivanthiran, B., Evans, K.S., DeVito, N.C., et al. (2020) A Tumor-Intrinsic PD-L1/NLRP3 Inflammasome Signaling Pathway Drives Resistance to Anti-PD-1 Immunotherapy. Journal of Clinical Investigation, 130, 2570-2586. [Google Scholar] [CrossRef] 
[32] 王玲, 蒲里津. 内皮细胞氧化应激对动脉粥样硬化发病过程的作用机制[J]. 微循环学杂志, 2022, 32(3): 66-70+78.
[33] Liu, X., Weng, X., Xiao, W., Xu, X., Chen, Y. and Chen, P. (2021) Pharmacological and Genetic Inhibition of PD-1 Demonstrate an Important Role of PD-1 in Ischemia-Induced Skeletal Muscle Inflammation, Oxidative Stress, and Angiogenesis. Frontiers in Immunology, 12, Article ID: 586429. [Google Scholar] [CrossRef] [PubMed]
[34] Tkachev, V., et al. (2015) Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism. Journal of Immunology (Baltimore, Md.: 1950), 194, 5789-5800.
[35] Jia, L., et al. (2021) Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors Exert Antiapoptosis and Antiinflammatory Activity in Lipopolysaccharide Stimulated Murine Alveolar Macrophages. Experi-mental and Therapeutic Medicine, 21, 400. [Google Scholar] [CrossRef] [PubMed]

为你推荐